The study and its comparison
Eighty-eight patients with septic shock and elevated lactate received intravenous thiamine or placebo in a blinded pilot. The primary outcome was lactate twenty-four hours after the first dose. [1]
The overall primary comparison was negative, as were overall shock-reversal and mortality comparisons. In the predefined subgroup with thiamine deficiency, lactate was lower with thiamine and a survival analysis suggested a possible benefit. [1]
What the finding establishes
Subgroup findings from a small trial need confirmation even when specified beforehand. The intravenous intensive-care setting cannot be extrapolated to oral energy supplements or a thiamine-magnesium combination. Funding and complete conflicts were not established from the abstract. A plausible metabolic role alone is insufficient to establish a general sepsis treatment effect. [1]
A hypothetical distinction
Imagine a predefined subgroup responds while the full cohort does not. Keep the overall result and the subgroup hypothesis separate.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Randomized, Double-Blind, Placebo-Controlled Trial of Thiamine as a Metabolic Resuscitator in Septic Shock: A Pilot Study.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.